Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1

Table 3 Progression-free survival and overall survival according to programmed cell death ligand 1 expression level

	Patients, n (%)	Progression-free survival (months)	P value2	Overall survival (months)	P value2
PD-L1 CPS < 11	19 (15)	22.4 (15.63-27.30)	P = 0.152	33.7 (NA)	P = 0.863
PD-L1 CPS ≥ 1	105 (85)	13.2 (14.91-20.10)		35.9 (16.84-55.02)
PD-L1 CPS < 5	60 (48)	16.7 (15.80-22.60)	P = 0.409	49.6 (20.89-78.97)	P = 0.746
PD-L1 CPS ≥ 5	64 (52)	12.1 (13.81-20.47)		30.1 (24.96-34.24)
PD-L1 CPS < 10	92 (74)	13.7 (15.35-20.77)	P = 0.529	49.9 (32.10-67.77)	P = 0.529
PD-L1 CPS ≥ 10	32 (26)	13.5 (13.52-23.45)		29.6 (21.65-37.49)

¹Programmed cell death ligand 1 expression was evaluated with various immunohistochemistry platforms using 22C3 antibody and determined with combined positive score.

²Kaplan-Meier methods and Cox-proportional hazards models were used for calculating P values and hazard ratios.

PD-L1: Programmed cell death ligand 1; CPS: Combined positive score.